MLchartDataset catalogue

Fexagratinib

Term · Oncology and biomedicine · MLC-T-ONC-013573

An orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) with potential antineoplastic activity. fexagratinib binds to and inhibits FGFR, which may result in the inhibition of FGFR-related signal transduction pathways, and, so, the inhibition of tumor cell proliferation and tumor cell death. FGFR, up-regulated in many tumor cell types, is a receptor tyrosine kinase essential to tumor cellular proliferation, differentiation and survival.

Table 1. Record
IdentifierMLC-T-ONC-013573
FieldOncology and biomedicine
SynonymsFGFR inhibitor AZD4547
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-013573",
  "term": "Fexagratinib",
  "field": "Oncology and biomedicine",
  "definition": "An orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) with potential antineoplastic activity. fexagratinib binds to and inhibits FGFR, which may result in the inhibition of FGFR-related signal transduction pathways, and, so, the inhibition of tumor cell proliferation and tumor cell death. FGFR, up-regulated in many tumor cell types, is a receptor tyrosine kinase essential to tumor cellular proliferation, differentiation and survival.",
  "synonyms": [
    "FGFR inhibitor AZD4547"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/fexagratinib/"
}

Record 7,241 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.